Tactile Medical to Release Third Quarter of Fiscal Year 2025 Financial Results on November 3, 2025

Rhea-AI Summary

Tactile Medical (Nasdaq: TCMD) announced it will release third quarter fiscal 2025 financial results after market close on Monday, November 3, 2025. Management will host a conference call with Q&A on November 3, 2025 at 5:00 p.m. ET.

Investors can join by phone at 877-407-3088 (international 201-389-0927) using access code 13755883, or listen via live webcast at investors.tactilemedical.com. A replay will be available for two weeks at 877-660-6853 (international 201-612-7415), access code 13755883. The webcast will be archived on the investor site.

About the company: Tactile Medical develops at-home therapies for chronic conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease to expand access and improve patient quality of life.

MINNEAPOLIS, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2025 financial results will be released after the market closes on Monday, November 3, 2025.

Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 3, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13755883. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13755883. The webcast will be archived at investors.tactilemedical.com.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Investor Inquiries:
Sam Bentzinger
Gilmartin Group
investorrelations@tactilemedical.com

FAQ

When will Tactile Medical (TCMD) release Q3 fiscal 2025 financial results?

Tactile Medical will release Q3 FY2025 results after market close on November 3, 2025.

What time is the TCMD earnings conference call on November 3, 2025?

The company will host a conference call with Q&A at 5:00 p.m. Eastern Time on November 3, 2025.

How can investors join the Tactile Medical (TCMD) November 3, 2025 call?

Dial 877-407-3088 (international 201-389-0927) and use access code 13755883, or join the live webcast at investors.tactilemedical.com.

Will there be a replay of the TCMD Q3 2025 conference call and how long will it be available?

Yes. A replay will be available for two weeks at 877-660-6853 (international 201-612-7415), access code 13755883.

Where will Tactile Medical archive the November 3, 2025 webcast?

The webcast will be archived on the company’s investor relations website at investors.tactilemedical.com.

What does Tactile Medical (TCMD) specialize in and why should investors care?

Tactile Medical develops at-home therapies for chronic conditions such as lymphedema and chronic pulmonary disease, which may affect patient access and care delivery.